Skip to Content


Maurie Markman, M.D., Named M. D. Anderson’s First Vice President for Clinical Research

Maurie Markman, M.D., Named M. D. Anderson’s First Vice President for Clinical Research
Newly created office to support clinical researchers within and outside institution

M. D. Anderson News Release 02/17/04

As part of a comprehensive effort to enhance the institution’s internationally-recognized clinical research program and to better serve the needs of its 600 clinical  investigators, The University of Texas M. D. Anderson Cancer Center has appointed the first vice president for clinical research.

Maurie Markman, M.D., has joined M. D. Anderson as the first to serve in this capacity.

According to M. D. Anderson’s Chief Academic Officer Margaret Kripke, Ph.D., Markman will be an advocate for clinical research, both within and outside M. D. Anderson. He also will work closely with the institution’s division heads, clinical department chairs and various internal committees that review and approve clinical research activities.

“The decision was made at the top level of the institution –– through internal and external review –– that the size and scope of the institution’s clinical research activities need someone who can help facilitate these programs, and also be an advocate at all levels of the administration,” says Kripke.

With more than 12,000 patients taking part last year, M. D. Anderson operates one of the largest clinical trials programs for cancer in the world. It is this clinical research, says Markman, for which the institution is renowned. M. D. Anderson’s clinical research blends patient care with the opportunity to learn from patients ways to improve their lives, while exploring new ways of treating, detecting and preventing cancer.

“Clinical research at M. D. Anderson has become a tremendous enterprise, both because of the size and growth of the institution, which has been extensive over the past few years, and because of the extraordinary opportunities in cancer:  new treatment strategies, new drugs and the profound understanding of the biology of the disease,” Markman says.

Markman says his office’s primary objective is to make it easier for researchers to conduct the highest quality clinical research at M. D. Anderson that can be done anywhere in the world.

“Before now, there was not an office devoted exclusively to the needs of, and advocating for, the clinical researcher, the person working with the patient directly carrying the research to the bedside,” Markman says. “One of the reasons that I was attracted to this position was the opportunity to do something that had not been done here before, and to do it in a manner that does not impede clinical research, but makes things easier for investigators, where the best-of-the-best work.”

Along with being an advocate for the clinical researcher at an institutional level, Markman plans to speak on behalf of clinical researchers to foundations, pharmaceutical and biotechnology companies and discuss research opportunities available at M. D. Anderson.

Markman will work collaboratively with M. D. Anderson’s Robert C. Bast, Jr., M.D., vice president for translational research, and Leonard A. Zwelling, M.D., vice president for research administration, to maximize opportunities for the institution’s strategic goal of advancing the level of research.

Before arriving at M. D. Anderson on Jan. 1, Markman served as director of the Cleveland Clinic Taussig Cancer Center in Ohio. He also served as chair of the Department of Hematology/Oncology at the Cleveland Clinic Foundation and held appointments as a professor of medicine at Ohio State University School of Medicine.

Markman’s major research interests are in the areas of gynecologic malignancies, particularly ovarian cancer, and in the development of novel management options for women with gynecologic cancers. He is a member of the American Society of Clinical Oncology, the American Association for Cancer Research and the International Gynecologic Cancer Society, among others. He is a fellow of the American College of Physicians and an associate member of the Society of Gynecologic Oncologists.

Markman earned his medical degree from New York Medical University School of Medicine. He holds a master of science degree in health policy and management from New York University Graduate School of Public Administration.

Upon receiving his Texas medical licensure, Markman will see patients at M. D. Anderson under the Department of Gynecologic Oncology.

© 2015 The University of Texas MD Anderson Cancer Center